Dystrophin analysis in clinical trials

Journal of Neuromuscular Diseases

Volumn 1, Issue 1, 2014, Pages 41-53

  Aartsma Rus, Annemieke ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Clinical trial; Duchenne muscular dystrophy; Dystrophin; Therapy; Western blotting

Indexed keywords

BIOLOGICAL MARKER; DYSTROPHIN;

CELL THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE THERAPY; HUMAN; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; STANDARDIZATION; STOP CODON; WESTERN BLOTTING;

EID: 84907474259     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-140013     Document Type: Review

References (54)

1. Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002; 82(2): 291-329.
2. Emery, A. E. The muscular dystrophies. Lancet. 2002; 359(9307): 687-695.
3. Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., and Kunkel, L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1): 90-95.
4. Hoffman, E. P., Brown, R. H., Jr., Kunkel, L. M. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987 Dec 24;51(6): 919-28.
5. Grounds, M. D. Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci. 2008; 65(11): 1621-1625.
6. Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., and Cripe, L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9(1): 77-93.
7. Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., and Cripe, L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: Implementation of multidisciplinary care. Lancet Neurol. 2010; 9(2): 177-189.
8. Koenig, M., Monaco, A. P., and Kunkel, L. M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 1988; 53(2): 219-228.
9. Lai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., and Long, C., et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009; 119(3): 624-635.
10. Aartsma-Rus, A., Van Deutekom, J. C., Fokkema, I. F., Van Ommen, G. J., and Den Dunnen, J. T. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006; 34(2): 135-144.
11. Vulin, A., Wein, N., Strandjord, D. M., Johnson, E. K., Find-lay, A. R., and Maiti, B., et al. The ZZ domain of dystrophin in DMD: Making sense of missense mutations. Hum Mutat. 2014; 35(2): 257-264.
12. Thomas, G. D. Functional muscle ischemia in Duchenne and Becker muscular dystrophy. Front Physiol. 2013; 4: 381.
13. Martin, E. A., Barresi, R., Byrne, B. J., Tsimerinov, E. I., Scott, B. L., and Walker, A. E., et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med. 2012; 4(162): 162ra155.
14. Pichavant, C., Aartsma-Rus, A., Clemens, P. R., Davies, K. E., Dickson, G., and Takeda, S., et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 2011; 19(5): 830-840.
15. Palmieri, B., Tremblay, J. P., and Daniele, L. Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy. Pediatr Transplant. 2010; 14(7): 813-819.
16. Malik, V., Rodino-Klapac, L. R., Viollet, L., Wall, C., King, W., and Al-Dahhak, R., et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol. 2010; 67(6): 771-780.
17. Finkel, R. S., Flanigan, K. M., Wong, B., Bonnemann, C., Sampson, J., and Sweeney, H. L., et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One. 2013; 8(12): e81302.
18. Mendell, J. R., Rodino-Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., and Lowes, L. P., et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013; 74(5): 637-647.
19. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., and Anthony, K., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet. 2011; 378(9791): 595-605.
20. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., and Adkin, C., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009; 8(10): 918-928.
21. Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., and Ekhart, P. F., Heuvelmans, N., et al. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med. 2011; 364(16): 1513-1522.
22. Van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., and Bremmer-Bout, M., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357(26): 2677-2686.
23. Aartsma-Rus, A. Overview on DMD exon skipping. Methods Mol Biol. 2012; 867: 97-116.
24. Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samul-ski, J. J., and Camp, A. S., et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012; 20(2): 443-455.
25. Van Deutekom, J. C., and Van Ommen, G. J. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003; 4(10): 774-783.
26. Skuk, D., Goulet, M., Roy, B., Chapdelaine, P., Bouchard, J. P., and Roy, R., et al. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol. 2006; 65(4): 371-386.
27. Tsigkos, S., Llinares, J., Mariz, S., Aarum, S., Fregonese, L., and Dembowska-Baginska, B., et al. Use of biomarkers in the context of orphan medicines designation in the European Union. Orphanet J Rare Dis. 2014; 9(1): 13.
28. Arechavala-Gomeza, V., Kinali, M., Feng, L., Guglieri, M., Edge, G., and Main, M., et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials. Neuromuscul Disord. 2010; 20(5): 295-301.
29. Arechavala-Gomeza, V., Kinali, M., Feng, L., Brown, S. C., Sewry, C., and Morgan. J. E., et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol. 2010; 36(4): 265-274.
30. Taylor, L. E., Kaminoh, Y. J., Rodesch, C. K., and Flanigan, K. M. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens. Neuropathol Appl Neurobiol. 2012; 38(6): 591-601.
31. Anderson, L. V., and Davison, K. Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol. 1999; 154(4): 1017-1022.
32. Ishikawa, Y., Ishikawa, Y., and Minami, R. Quantitative estimation of dystrophin protein: A sensitive and convenient “two-antibody sandwich” ELISA. Tohoku J Exp Med. 1996; 180(1): 57-63.
33. Brown, K. J., Marathi, R., Fiorillo, A. A., Ciccimaro, E. F., Sharma, S., and Rowlands, D. S., et al. Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. J Bioanal Biomed. 2012; Suppl 7.
34. Escher, C., Lochmuller, H., Fischer, D., Frank, S., Reimann, J., and Walter, M. C., et al. Reverse protein arrays as novel approach for protein quantification in muscular dystrophies. Neuromuscul Disord. 2010; 20(5): 302-309.
35. Cirak, S., Feng, L., Anthony, K., Arechavala-Gomeza, V., Torelli, S., and Sewry, C., et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther. 2012; 20(2): 462-467.
36. Beekman, C., Testerink, J., Giannakopoulos, S., Kreuger, D., Sipkens, J., and Van Deutekom, J. C., et al. An objective method for immunofluorescence analysis of dystrophin levels in muscle from DMD patients in clinical studies. Neuromuscul Disord. 2013; 23(9-10): 812. Meeting report
37. Lourbakos, A., beekman, C., Holling, T., Testerink, J., Duins-bergen, D., and Giannakopoulos, S., et al. Bioanalysis of a double blind, placebo-controlled clinical phase 2 study of drisapersen for the treatment of boys suffering from Duchenne muscular dystrophy and comparison to clinical outcome results. Neuromuscul Disord. 2013; 23(9-10): 805. Meeting report
38. Aartsma-Rus, A., Janson, A. A., Kaman, W. E, Bremmer-Bout, M., Den Dunnen, J. T., and Baas, F., et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003; 12(8): 907-914.
39. Muntoni, F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord. 2010; 20(5): 355-362.
40. Aartsma-Rus, A., and Muntoni, F. 194th ENMC international workshop. 3rd ENMC workshop on exon skipping: Towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naar-den, The Netherlands. Neuromuscul Disord. 2013; 23(11): 934-944.
41. Spitali, P., van den Bergen, J. C., Verhaart, I. E., Wokke, B., Janson, A. A., and van den Eijnde, R., et al. DMD transcript imbalance determines dystrophin levels. FASEB J. 2013; 27(12): 4909-4916.
42. Veltrop, M., van der Kaa, J., Claassens, J., van, V. L., Verbeek, S., and Aartsma-Rus, A. Generation of embryonic stem cells and mice for duchenne research. PLoS Curr. 2013; 5.
43. Wokke, B. H., van den Bergen, J. C., Versluis, M. J., Niks, E. H., Milles, J., and Webb, A. G., et al. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul Disord. 2014.
44. Henricson, E., Abresch, R., Han, J. J., Nicorici, A., Goude, K. E., and de, B. E., et al. The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: Longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr. 2013; 5.
45. Pane, M., Mazzone, E. S., Sormani, M. P., Messina, S., Vita, G. L., and Fanelli, L., et al. 6 minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One. 2014; 9(1): e83400.
46. Goemans, N., van den Hauwe, M., Wilson, R., van, I. A., Klingels, K., and Buyse, G. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord. 2013; 23(8): 618-623.
47. McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J. M, Eagle, M., and Gappmaier, E., et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013; 48(3): 343-356.
48. Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., and Loike, J.D., et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med. 1988; 318(21): 1363-1368.
49. van Putten, M., Hulsker, M., Young, C., Nadarajah, V. D., Heemskerk, H., and van der Weerd, L., et al. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J. 2013; 27(6): 2484-2495.
50. Li, D., Yue, Y., and Duan, D. Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. PLoS One. 2010; 5(12): e15286.
51. Mirza, A., Sagathevan, M., Sahni, N., Choi, L., and Menhart, N. A biophysical map of the dystrophin rod. Biochim Biophys Acta. 2010; 1804(9): 1796-1809.
52. Le, R. E., Hubert, J. F., Winder, S. J. A new twist to coiled coil. FEBS Lett. 2012; 586(17): 2717-2722.
53. Flanigan, K. M., Voit, T., Rosales, X. Q., Servais, L., Kraus, J. E., Wardell, C., et al. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial. Neuromuscul Disord. 2014; 24(1): 16-24.
54. Hirawat, S., Welch, E. M., Elfring, G. L., Northcutt, V. J., Paushkin, S., and Hwang, S., et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007; 47(4): 430-444.